Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

June 1, 2017

OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany

News

One World Cannabis Pharmaceutical Research (OWCP) and mediq Innovation Experts have partnered to introduce OWCP’s cannabinoid-based topical psoriasis cream in Germany. Germany-based mediq has extensive experience in assisting companies based in ... Read more

May 4, 2017May 4, 2017

FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients

News

The U.S. Food and Drug Administration (FDA) will review Pfizer’s medication Xeljanz (tofacitinib citrate) 5 mg twice daily, to treat adults with active psoriatic arthritis (PsA) who had an inadequate response to conventional treatments, ... Read more

April 27, 2017April 27, 2017

Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month

News

Siliq (brodalumab) injection, recently approved to treat adults with severe plaque psoriasis, will be available in the U.S. at a list price of $3,500 per month, Valeant Pharmaceuticals announced. The announcement ... Read more

April 20, 2017April 20, 2017

XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata

News

XTRAC targeted-light therapy safely treats skin lesions in psoriasis patients without the serious side effects linked to Humira and other conventional psoriasis drugs, says XTRAC’s manufacturer, Strata Skin Sciences of Horsham, Pa. The ... Read more

April 18, 2017April 18, 2017

National Psoriasis Foundation Grants Seal of Recognition to MetaDerm Heal & Prevent Psoriasis Cream

News

The National Psoriasis Foundation (NPF) has given its Seal of Recognition to MetaDerm Heal & Prevent Cream, a therapeutic botanical cream for psoriasis made by Haus Bioceuticals. MetaDerm — one of the first botanical-based therapeutic products to ... Read more

April 13, 2017April 13, 2017

EIU Report Urges More Government Action in Europe, Canada for People Living with Psoriasis

News

Since 2014, governments around the world have not done enough to improve the care of people living with psoriasis, says a new report issued by the Economist Intelligence Unit (EIU). Pharmaceutical giant Eli ... Read more

April 11, 2017

Cannabinoid-Based Topical Cream for Psoriasis Receiving Interest from Scientific Community

News

A cannabinoid-based topical cream to treat psoriasis is receiving interest from the global scientific and medical communities, according to the developer of the cream, One World Cannabis (OWC) Pharmaceutical Research company. ... Read more

April 6, 2017April 6, 2017

Filgotinib in Phase 2 Trials for Psoriatic Arthritis, Sjogren’s Syndrome and Ankylosing Spondylitis

News

Galapagos has initiated three Phase 2 clinical trials to evaluate filgotinib for the treatment of psoriatic arthritis, Sjogren’s syndrome, and ankylosing spondylitis. According to a press release, in psoriatic arthritis, the therapeutic ... Read more

April 4, 2017April 4, 2017

FDA Adds Fingernail Psoriasis to Prescribing Information for AbbVie’s Humira Therapy

News

The U.S. Food and Drug Administration (FDA) has approved the inclusion of fingernail psoriasis in prescribing information for Humira (adalimumab, AbbVie) a drug used by patients with moderate to severe chronic ... Read more

March 28, 2017March 28, 2017

EU Approves Amgevita for Treatment of Plaque Psoriasis, Other Inflammatory Diseases

News

The European Union has approved Amgen’s Amgevita (a biosimilar to AbbVie’s Humira, adalimumab) to treat moderate to severe chronic plaque psoriasis, as well as other inflammatory diseases. This EU approval follows a positive opinion ... Read more